Second-line treatment of Non-Small Cell Lung Cancer (NSCLC) with erlotinib is potentially cost-saving for the German healthcare system.
| Autor: | Gatzemeier, Ulrich, Pirk, Olaf, Gabriel, Anja, Erhardt, Wilma, Kotowa, Wioletta |
|---|---|
| Zdroj: | Journal of Thoracic Oncology; 2007 Supplement 4, Vol. 2, pS714-S715, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|